Logo

PharmaShots Weekly Snapshots (February 21-25, 2022)

Share this

PharmaShots Weekly Snapshots (February 21-25, 2022)

Centessa Reports the First Patient Dosing in the P-III (ACTION) Study of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease

Published: Feb 25, 2022 | Tags: Centessa, P-III, ACTION Study, Autosomal Dominant, Polycystic Kidney Disease

Immunocore Receives EMA’s CHMP Positive Opinion for Kimmtrak (tebentafusp) to Treat Unresectable or Metastatic Uveal Melanoma

Published: Feb 25, 2022 | Tags: Immunocore, EMA, CHMP, Kimmtrak, tebentafusp, Uveal Melanoma

Moderna Receives EMA's CHMP Positive Opinion Recommending Conditional Marketing Authorization of Spikevax (COVID-19 vaccine) for COVID-19

Published: Feb 25, 2022 | Tags: Moderna, EMA, CHMP, Conditional Marketing Authorization, Spikevax, COVID-19

Genmab & Seagen Present Preliminary Results of Tivdak (tisotumab vedotin) in P-II (innovaTV 207) Trial for Head & Neck Squamous Cell Carcinoma at ASTRO 2022

Published: Feb 25, 2022 | Tags: Genmab, Seagen, Tivdak, tisotumab vedotin, P-II, innovaTV 207 Trial, Head, Neck, Squamous Cell Carcinoma, ASTRO 2022

AbbVie Reports Results of Rinvoq (upadacitinib) in P-III (U-EXCEL) Induction Study for the Treatment of Crohn's Disease

Published: Feb 25, 2022 | Tags: AbbVie, Rinvoq, upadacitinib, P-III, U-EXCEL, Induction Study, Crohn's Disease

Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) Receive the US FDA’s Approval to Treat Adults with HFpEF

Published: Feb 25, 2022 | Tags: Boehringer Ingelheim, Eli Lilly, Jardiance, empagliflozin, US, FDA, Approval, Heart Failure Left Ventricular Ejection Fraction

Vaxcyte Reports the First Patient Dosing of VAX-24 in P-I/II Study for the Prevention of Invasive Pneumococcal Disease and Pneumonia

Published: Feb 24, 2022 | Tags: Vaxcyte, VAX-24, P-I/II Study, Invasive Pneumococcal Disease, Pneumonia

Jacobio Reports the Completion of First Patient Dosing of JAB-21822 + Cetuximab in Clinical Trials for the Treatment of Colorectal Cancer

Published: Feb 24, 2022 | Tags: Jacobio, JAB-21822, Cetuximab, Colorectal Cancer

Aadi Bioscience Launches Fyarro for the Treatment of Adult Patients with Malignant PEComa

Published: Feb 24, 2022 | Tags: Aadi Bioscience, Fyarro, Malignant PEComa

Horizon Initiates P-III (OPTIC-J) Trial of Teprotumumab for the Treatment of Active Thyroid Eye Disease

Published: Feb 24, 2022 | Tags: Horizon, P-III, OPTIC-J Trial, Teprotumumab, Thyroid Eye Disease

Alimera Sciences Publishes Three Year Results of Iluvien in P-IV (PALADIN) Study for the Treatment of DME in Peer-Reviewed Journal Ophthalmology

Published: Feb 24, 2022 | Tags: Alimera Sciences, Iluvien, P-IV, PALADIN Study, DME, Ophthalmology

Cytokinetics Initiates P-III (SEQUOIA-HCM) Trial of Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Published: Feb 24, 2022 | Tags: Cytokinetics, P-III, SEQUOIA-HCM Trial, Aficamten, Symptomatic, Obstructive, Hypertrophic Cardiomyopathy

Kodiak Reports Results of KSI-301 in P-IIb/III Study for the Treatment of Age-Related Macular Degeneration

Published: Feb 23, 2022 | Tags: Kodiak, KSI-301, P-IIb/III Study, Age-Related Macular Degeneration

Medtronic’s InterStim X System Receives the US FDA’s Approval for the Treatment of Bladder and Bowel Control

Published: Feb 23, 2022 | Tags: Medtronic, InterStim X System, US, FDA, Approval, Bladder, Bowel Control

BioXcel Publishes Results of BXCL501 in P-III (SERENITY II) Trial for the Treatment of Bipolar Disorders in the JAMA

Published: Feb 23, 2022 | Tags: BioXcel, BXCL501, P-III, SERENITY II Trial, Bipolar Disorders, JAMA

Kiniksa Collaborated with Huadong Medicine to Develop and Commercialize Arcalyst and Mavrilimumab for Autoimmune and Inflammatory Diseases

Published: Feb 23, 2022 | Tags: Kiniksa, Huadong Medicine, Arcalyst, Mavrilimumab, Autoimmune, Inflammatory Diseases

Takeda Entered into a Collaboration and Option Agreement with Code Bio to Develop Gene Therapies for the Treatment of Rare Diseases

Published: Feb 23, 2022 | Tags: Takeda, Code, Gene Therapies, Rare Diseases 3DNA, Non-Viral, Genetic Medicine

Akebia Amended and Restated License Agreement with Vifor Pharma to Launch Vadadustat in the US

Published: Feb 23, 2022 | Tags: Akebia, Vifor Pharma, Vadadustat, US, Anemia, CKD

OBI Entered into an Exclusive License Agreement with Odeon for OBI-999 and OBI-833 to Treat Cancer in China, Hong Kong and Macau

Published: Feb 22, 2022 | Tags: OBI, Odeon, OBI-999, OBI-833, Cancer, China, Hong Kong, Macau

InnoCare Reports First Patient Dosing of Orelabrutinib in P-II Clinical Trial for the Treatment of ITP

Published: Feb 22, 2022 | Tags: InnoCare, Orelabrutinib, P-II, Clinical Trial, ITP

Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Clinical Trial for the Treatment of Active Crohn's Disease at ECCO 2022

Published: Feb 22, 2022 | Tags: Janssen, Tremfya, guselkumab, P-II, GALAXI 1 Clinical Trial, Active Crohn's Disease

Abbott's CardioMEMS HF System Receives the US FDA’s Approval for the Treatment of Heart Failure

Published: Feb 22, 2022 | Tags: Abbott, CardioMEMS HF System, US, FDA, Approval, Heart Failure

Ono’s Velexbru Receives the TFDA’s Approval for the Treatment of B-cell Primary Central Nervous System Lymphoma in Taiwan

Published: Feb 22, 2022 | Tags: Ono, Velexbru, TFDA, Approval, B-cell Primary Central Nervous System Lymphoma, Taiwan

BioNTech Entered into a Research Collaboration with Medigene to Boost T Cell Receptor Immunotherapies Against Cancer

Published: Feb 22, 2022 | Tags: BioNTech, Medigene, T Cell, Receptor, Immunotherapies, Cancer

Medtronic’s Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters Receives the US FDA’s Expanded Approval for AVNRT

Published: Feb 21, 2022 | Tags: Medtronic, Freezor, Xtra Cardiac Cryoablation Focal Catheters, US, FDA, Expanded Approval,  AVNRT

Immunic Presents Preclinical Data of IMU-838 9 (vidofludimus calcium) in P-II (CALDOSE-1) Trial for the Treatment of Ulcerative Colitis at ECCO 2022

Published: Feb 21, 2022 | Tags: Immunic, IMU-838 9, vidofludimus calcium, P-II, CALDOSE-1 Trial, Ulcerative Colitis, ECCO 2022

Agios’ Pyrukynd (mitapivat) Receives the US FDA’s Approval as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with PK Deficiency

Published: Feb 21, 2022 | Tags: Agios, Pyrukynd, mitapivat, US, FDA, Approval, Hemolytic Anemia, PK Deficiency

EMD Serono Reports Results of Bavencio (avelumab) in P-III (JAVELIN Bladder 100) Trial as 1L Maintenance Treatment for Advanced Urothelial Carcinoma

Published: Feb 21, 2022 | Tags: EMD Serono, Bavencio, avelumab, P-III, JAVELIN Bladder 100 Trial, Urothelial Carcinoma

Eli Lilly Reports Results of Mirikizumab in P-III (LUCENT-1) Induction Study for the Treatment of Ulcerative Colitis

Published: Feb 21, 2022 | Tags: Eli Lilly, Mirikizumab, P-III, LUCENT-1, Induction Study, Ulcerative Colitis

Janssen Reports Results of Tremfya (guselkumab) in P-IIb (QUASAR) Induction Study for the Treatment of Active Ulcerative Colitis

Published: Feb 21, 2022 | Tags: Janssen, Tremfya, guselkumab, P-IIb, QUASAR, Induction Study, Ulcerative Colitis

Related Post: PharmaShots Weekly Snapshots (February 14-18, 2022)


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions